• Anteris Technologies began U.S. enrollment in its global pivotal PARADIGM trial, treating first U.S. patients with its DurAVR transcatheter heart valve system for severe calcific aortic stenosis.
• No trial results have been presented; study is positioned to generate evidence intended to guide future patient care.
• Early procedural experience in initial U.S. cases was described as encouraging, with trial design aimed at assessing broader patient recovery effects beyond standard safety measures.
• First U.S. procedures were performed at Montefiore Medical Center in New York, marking start of expanded U.S. recruitment capacity for the global study.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Anteris Technologies Global Corp. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605050600PRIMZONEFULLFEED9713172) on May 05, 2026, and is solely responsible for the information contained therein.